Evidence map›Paper›PMID 24098655›Full record

ArticlePloS one2013

A small volatile bacterial molecule triggers mitochondrial dysfunction in murine skeletal muscle.

A Aria Tzika, Caterina Constantinou, Arunava Bandyopadhaya, Nikolaos Psychogios, Sangseok Lee, Michael Mindrinos, J A Jeevendra Martyn, Ronald G Tompkins, Laurence G Rahme

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 43 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Article
  2. Article
  3. Revealing the impact ofFrontiers in immunology · 2025
    Article
  4. Frontiers in immunology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Mitochondria as a Cellular Hub in Infection and Inflammation.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Thriving Under Stress:Frontiers in cellular and infection microbiology · 2020
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A Aria TzikaDepartment of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Athinoula A. Martinos Center of Biomedical Imaging, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Shriners Hospitals for Children Boston, Boston, Massachusetts, United States of America.
Caterina Constantinou
Arunava Bandyopadhaya
Nikolaos Psychogios
Sangseok Lee
Michael Mindrinos
J A Jeevendra Martyn
Ronald G Tompkins
Laurence G Rahme
Harvard University · USShriners Hospitals for Children - Boston · USMassachusetts General Hospital · USStanford University · US

Funding

Interruption of Signaling-Mediated Bacterial Persistent InfectionsR33AI105902 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAHME, LAURENCE G · 2015 to 2017
$1.8M
Interruption of Signaling-Mediated Bacterial Persistent InfectionsR21AI105902 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAHME, LAURENCE G · 2013 to 2014
$478k
NIAID NIH HHS R21 AI105902NIAID NIH HHS R33 AI105902
6 · The paper itself

Abstract

Mitochondria integrate distinct signals that reflect specific threats to the host, including infection, tissue damage, and metabolic dysfunction; and play a key role in insulin resistance. We have found that the Pseudomonas aeruginosa quorum sensing infochemical, 2-amino acetophenone (2-AA), produced during acute and chronic infection in human tissues, including in the lungs of cystic fibrosis (CF) patients, acts as an interkingdom immunomodulatory signal that facilitates pathogen persistence, and host tolerance to infection. Transcriptome results have led to the hypothesis that 2-AA causes further harm to the host by triggering mitochondrial dysfunction in skeletal muscle. As normal skeletal muscle function is essential to survival, and is compromised in many chronic illnesses, including infections and CF-associated muscle wasting, we here determine the global effects of 2-AA on skeletal muscle using high-resolution magic-angle-spinning (HRMAS), proton ((1)H) nuclear magnetic resonance (NMR) metabolomics, in vivo (31)P NMR, whole-genome expression analysis and functional studies. Our results show that 2-AA when injected into mice, induced a biological signature of insulin resistance as determined by (1)H NMR analysis-, and dramatically altered insulin signaling, glucose transport, and mitochondrial function. Genes including Glut4, IRS1, PPAR-γ, PGC1 and Sirt1 were downregulated, whereas uncoupling protein UCP3 was up-regulated, in accordance with mitochondrial dysfunction. Although 2-AA did not alter high-energy phosphates or pH by in vivo (31)P NMR analysis, it significantly reduced the rate of ATP synthesis. This affect was corroborated by results demonstrating down-regulation of the expression of genes involved in energy production and muscle function, and was further validated by muscle function studies. Together, these results further demonstrate that 2-AA, acts as a mediator of interkingdom modulation, and likely effects insulin resistance associated with a molecular signature of mitochondrial dysfunction in skeletal muscle. Reduced energy production and mitochondrial dysfunctional may further favor infection, and be an important step in the establishment of chronic and persistent infections.

Indexed as

AcetophenonesAdenosine TriphosphateAnimalsBlotting, WesternGene Expression RegulationHumansInsulin ResistanceMagnetic Resonance SpectroscopyMetabolomicsMiceMicroarray AnalysisMitochondrial DiseasesMuscle, SkeletalPseudomonas aeruginosaQuorum SensingTetrazolium SaltsacetophenoneAcetophenonesAdenosine TriphosphateTetrazolium SaltsThiazolesthiazolyl blue

Identifiers

PMID24098655
PMCPMC3787027
OpenAlexW2158141398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.